清亮细胞型肝细胞癌（HCC）是一种罕见的肿瘤，与普通型HCC相比，预后存在矛盾情况。首先，从监测、流行病学和最终结果（SEER）数据库中选取清亮细胞型和普通型HCC患者，并确定他们的人口统计学和临床特征。随后，进行两种HCC类型的总体生存率（OS）、疾病特异性生存率（DSS）和亚组分析。接下来，我们利用竞争风险模型，重点关注癌症导致的死亡。最后，根据组织病理学类型采用倾向性评分匹配（PSM）以减少混杂因素，并进行敏感性分析。我们研究中共收集了205例清亮细胞型HCC和29,954例普通型HCC。清亮细胞型HCC患者的年龄较大，女性为主，相比普通型HCC患者。两组之间的OS和DSS没有显著差异，而发病病理类型不是HCC的预后因素，竞争风险模型已经验证。由PSM和敏感性分析调整的患者特征证实了这个结论。在亚组分析中，III ~IV级清亮细胞型HCC患者和淋巴结转移的患者相比普通型HCC的预后更好。本研究揭示了清亮细胞型HCC的预后与普通型HCC相似。肿瘤分化程度和淋巴结转移情况影响HCC的预后。© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Clear cell type hepatocellular carcinoma (HCC) is an uncommon neoplasm with an ambivalent prognosis compared to common type HCC.First, patients with clear cell or common type HCC were enrolled from the Surveillance, Epidemiology, and End Results (SEER) database, and their demographic and clinical characteristics were identified. Next, overall survival (OS), disease-specific survival (DSS), and subgroup analysis of the two types of HCC were performed. Next, we utilized a competing risk model to focus on cancer-caused death. Finally, propensity score matching (PSM) was employed to reduce the confounding factors based on the histopathological type, and sensitivity analysis was conducted.A total of 205 cases of clear cell type HCC and 29,954 cases of common type HCC were enrolled in our study. Patients with clear cell type HCC were older and predominantly female than those with common type HCC. OS and DSS were not significantly different between the two groups, and histopathological type was not a prognostic factor of HCC, as verified by the competing risk model. Patient characteristics adjusted by PSM and sensitivity analysis confirmed this conclusion. In subgroup analysis, patients with clear cell type HCC at grade III ~ IV and with lymph nodes metastasis had a better prognosis compared to common type HCC.This study revealed that the prognosis of clear cell type HCC is similar to common type HCC. Tumor differentiation grade and status of lymph node metastasis affect the prognosis of HCC.© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.